RE:RE:RE:RE:RE:PP speculationDJDawg wrote: I recall that there was mention of getting 5m to be shelf prospectus worthy. Is a shelf prospectus just a bunch of shares on the shelf ready for the compay to play out as needed? But no warrants?
DJ, What do you think of this? ------------------- "RuvidarTM, combined with transferrin to form the compound Rutherrin, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC")." ------------------- Theralase has demonstrated that all animals treated with x-ray activated Rutherrin are currently alive; unfortunately, this is not the case for mice that received x-ray treatment only. "In addition, the mice treated with x-ray activated Rutherrin have demonstrated up to a 4-fold slower tumour progression, based on the Magnetic Resonance Imaging ("MRI") assessment of tumour volumes." ---------------------- "there is a significant delay in tumour progression in mice treated with x-ray activated Rutherrin versus with radiation alone (p> 0.001). In fact, in mice treated with x-ray activated Rutherrin, the tumour is notably regressing / being destroyed over time." ------------------------- "In fact, in mice treated with x-ray activated Rutherrin, the tumour is notably regressing / being destroyed over time."